Compare Adaptive Biotechnologies Corp (ADPT) vs United States Natural Gas Fund (UNG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs United States Natural Gas Fund — how do they compare? Adaptive Biotechnologies Corp trades at $25.41 (market cap $4.04B), while United States Natural Gas Fund trades at $10.2. The key difference: Adaptive Biotechnologies Corp is trading nearer its 52-week high, United States Natural Gas Fund nearer its low. Which is the better fit depends on your goals.
| ADPT | UNG | |
|---|---|---|
Market Cap | $4.04B | — |
Sector | Health | Commodities - Energy |
52-Week High | $25.45 | $16.90 |
52-Week Low | $12.30 | $9.63 |
Enterprise Value | $4.10B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Adaptive Biotechnologies (ADPT) trades at $25.24, near its 52-week high, with a bullish technical outlook. The company is executing a strategic separation into a pure-play MRD diagnostics business, showing strong revenue growth of 49% year-over-year in MRD and improving margins. Despite persistent net losses, cash flow turned positive in 2025, and recent earnings have mostly beaten expectations, indicating operational progress.
The outlook is cautiously optimistic, driven by the business separation potentially unlocking value and the MRD segment's growth. Key risks include sustained profitability challenges and high valuation multiples. Analyst consensus is bullish with a $25.50 price target, but investors should weigh the growth potential against the company's current lack of earnings.
UNG, the United States Natural Gas Fund, trades at $10.23, up 0.89% on the day, with technical indicators showing a bearish bias from moving averages but neutral oscillators. The fund tracks natural gas futures, with recent news highlighting steady prices amid weather-driven demand shifts and geopolitical tensions affecting commodity markets. Key support and resistance cluster around $10, indicating a critical price zone.
The outlook for UNG hinges on natural gas supply-demand dynamics, with EIA forecasting record highs in 2026, but risks include volatility from weather patterns and Middle East conflicts. Investment appeal lies in exposure to energy themes, though the fund's structure as a futures tracker may lead to divergence from spot prices, as noted in comparative analyses with equity-based ETFs like FCG.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About United States Natural Gas Fund
UNG is a commodity ETF that tracks the daily price movements of natural gas futures. It primarily invests in front-month contracts at the Henry Hub, making it a highly volatile tool for short-term trading rather than long-term holding due to contango and roll costs.
Read more on UNG →
